20 reports

South Korea Cell Culture Market by Product (Consumables and Instruments), Application (Stem Cell Technology, Cancer Research, Drug Screening and Development, Tissue Engineering & Regenerative Medicine, and Others), and End User (Research Institutes, Pharmaceutical & Biotechnology Companies, and Others): Opportunity Analysis and Industry...

  • Cell Therapy
  • South Korea

European Union Germany Therapy Monoclonal Antibody Biopharmaceutical Hospital

  • Pharmaceutical
  • Biopharmaceutical
  • Japan
  • Taiwan
  • South Korea
  • Drug Approval

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

  • Pharmaceutical
  • Biopharmaceutical
  • Healthcare
  • Biotechnology
  • World
  • South Korea
  • China

Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

  • Pharmaceutical
  • Biopharmaceutical
  • Healthcare
  • South Korea
  • United States
  • World

INTRODUCTION Since the approval of the first therapy, Genedicine® in 2003, the gene therapy domain has evolved significantly. Specifically, in 2019, three gene therapies, namely Zolgensma® (US), Zynteglo™ (Europe) and Beperminogene Perplasmid (Japan), have received approval / conditional approval, leading to a marked upward...

  • Gene Therapy
  • World
  • United States
  • Europe
  • Japan
  • APAC
  • China
  • South Korea
  • Australia
  • Drug Approval
  • Number Of Enterprises

Monoclonal Antibody Biopharmaceutical

  • Biosimilar
  • India
  • United States
  • South Korea
  • Japan
  • Biosimilar Penetration Rate
  • Biosimilar Approvals

Karnataka World India Biopharmaceutical Autoimmune Disease

  • Biosimilar
  • United States
  • India
  • Japan
  • South Korea
  • Biosimilar Penetration Rate
  • Biologics Penetration Rate

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5...

  • Biopharmaceutical
  • Biosimilar
  • Asia
  • South Korea
  • India
  • World

AstraZeneca plc, a biopharmaceutical company, has formed a joint venture (JV) with Samsung Biologics Co Ltd., a biopharmaceutical company, to develop a biosimilar using the combined capabilities of the partners.

  • Biopharmaceutical
  • Pharmaceutical
  • Healthcare
  • World
  • South Korea
  • Prescription Drug Sales
  • Biosimilar Penetration Rate

YZY Biopharma Homepage June - Ybodies are asymmetric bispecific antibodies based on an whole IgG format with knob-into-hole and salt bridge strategy resulting in high effifiency of heterodimerization production.

  • Immunotherapy
  • World
  • China
  • United States
  • South Korea
  • Drug Approval
  • Manufacturing Output

Organovo partners with biopharmaceutical companies and academic medical centers to design, build, and validate more predictive in vitro tissues for disease modeling and toxicology.

  • 3D Printing
  • Cell Therapy
  • Application
  • Open Source
  • United States
  • South Korea
  • Europe
  • Singapore
  • Asia
  • Meat Production
  • Health Provider Density

Merck Biopharma

  • Immunotherapy
  • Monoclonal Antibody
  • Cancer
  • China
  • United States
  • World
  • South Korea

Summary Crucell NV (Crucell) is a biopharmaceutical company. It discovers, develops, manufactures and markets vaccines and antibodies indicated against infectious diseases. Its product portfolio comprises marketed products, vaccines under development and development stage antibodies. The company’s range of marketed vaccine is...

  • Pharmaceutical
  • Infectious Disease
  • Biopharmaceutical
  • Sexually Transmitted Disease
  • Healthcare
  • Research And Development
  • Influenza
  • Europe
  • APAC
  • China
  • Netherlands
  • North America
  • South Korea
  • Middle East
  • Italy
  • United Kingdom
  • Spain
  • Sweden
  • Africa
  • Switzerland

Merck Biopharma

  • Immunotherapy
  • Monoclonal Antibody
  • Cancer
  • China
  • United States
  • World
  • South Korea

Epirus Biopharmaceuticals – ##/##

  • Biosimilar
  • United States
  • European Union
  • Japan
  • World
  • China
  • South Korea
  • Auto-Immune Diseases Prevalence

Soligenix, Inc. (formerly DOR BioPharma, Inc.) is a development stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.

  • Pharmaceutical
  • Biopharmaceutical
  • Private Placement
  • Healthcare
  • South Korea
  • Prescription Drug Sales
  • Dates Price

Biotherapeutics Inc Italy Biopharmaceutical

  • Biopharmaceutical
  • Italy
  • South Korea
  • Dates Price

EGIS Pharmaceuticals PLC, a Hungary-based pharmaceutical company, has signed a entered into a collaboration agreement with Celltrion, Inc. and Celltrion Healthcare Co., Ltd. (together Celltrion Group) for the distribution of biopharmaceutical products developed and manufactured by Celltrion based on FDA and EMA standard.

  • Pharmaceutical
  • Biopharmaceutical
  • Healthcare
  • Private Placement
  • South Korea
  • United States
  • United Kingdom
  • Printed Circuit Board Production
  • Dates Price

Biosimilars are highly-similar versions of biological drugs that are indicated for cancer, kidney disorders and a wide range of autoimmune diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many of them cost nearly $100,000 per patient per year. These expensive biologics impose a heavy financial...

  • Biopharmaceutical
  • Biosimilar
  • World
  • India
  • United States
  • South Korea
  • European Union
  • Biosimilar Approvals
  • Drug Approval

South Korea has emerged as one of the strategic location for the development of biosimilars on the global level. Among the various emerging countries identified for development of biosimilars, South Korea is one of the most promising countries where pharmaceutical companies have identified huge investment potentials for the drug development...

  • Biosimilar
  • South Korea